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Abstract: The use of needles for multiple injection of drugs, such as insulin for diabetes, can be 
painful. As a result, prescribed drug noncompliance can result in severe medical complications. 
Several noninvasive methods exist for transdermal drug delivery. These include chemical media-
tion using liposomes and chemical enhancers or physical mechanisms such as microneedles, 
iontophoresis, electroporation, and ultrasound. Ultrasound enhanced transdermal drug delivery 
offers advantages over traditional drug delivery methods which are often invasive and painful. 
A broad review of the transdermal ultrasound drug delivery literature has shown that this technol-
ogy offers promising potential for noninvasive drug administration. From a clinical perspective, 
few drugs, proteins or peptides have been successfully administered transdermally because of 
the low skin permeability to these relatively large molecules, although much work is underway 
to resolve this problem. The proposed mechanism of ultrasound has been suggested to be the 
result of cavitation, which is discussed along with the bioeffects from therapeutic ultrasound. 
For low frequencies, potential transducers which can be used for drug delivery are discussed, 
along with cautions regarding ultrasound safety versus efﬁ  cacy.
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Introduction
Several methods exist for improving transdermal drug delivery such as chemical 
mediation using liposomes or chemical enhancers, and physical mechanisms such 
as iontophoresis, lasers, electroporation, microneedles and ultrasound (also called 
sonophoresis or phonophoresis) (Prausnitz 1997; Prausnitz 1999; Montorsi et al 
2000; Wang et al 2005; Nanda et al 2006). Numerous studies of these methods have 
shown that ultrasound mediated transdermal drug delivery offers promising potential 
for noninvasive drug administration. However the broad literature on ultrasound 
drug delivery is not conﬁ  ned only to transdermal applications. A large body of work 
focuses speciﬁ  cally on delivery to internal organs, but does not cover tissues or gene 
delivery. Additionally for transdermal work, the reader is also directed to several well 
written articles for further reading and additional viewpoints on this topic (Mitragotri 
and Kost 2004; Pitt et al 2004; Brown et al 2006).
Passive drug delivery across the stratum corneum can be transported with molecules 
that have a weight less than 500 Da (Brown et al 2006). In general the stratum cor-
neum, which varies in thickness (≈ 10–20 μm) depending on the body location, forms 
the barrier to drug diffusion. This low permeability is attributed to the outermost skin 
layer that consists of a compact and organized structure of cells named keratinocites 
surrounded by lipid bilayers. Ultrasound enhanced transdermal drug delivery offers 
advantages over traditional injection drug delivery methods which are invasive and 
painful. Currently few drugs, proteins or peptides have been successfully administered 
transdermally for clinical applications because of the low skin permeability to these 
relatively large molecules. However from a research viewpoint, the list of compounds International Journal of Nanomedicine 2007:2(4) 586
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which have been shown to transdermally cross skin via ultra-
sound is ever increasing. One hypothesis indicates that once 
the drug has traversed the stratum corneum, the next layer is 
easier to cross and subsequently the drug can reach the capil-
lary vessels to be absorbed (Mitragotri et al 1995b).
Background on ultrasound delivery 
and biological effects
One of the earliest reports of the interaction between ultra-
sound and biological tissue can be traced back to the 1920s 
and the post-World War I experiments of Professor Paul 
Langévin (Graff 1981). Much of his work centered on the 
development of pulse-echo sonar for submarine detection, 
including the observation of bubble formation in the water 
and the killing of ﬁ  sh from the sound beam. Speciﬁ  c biologi-
cal changes such as searing of skin, rupturing of red blood 
cells and lethal effects on mammals were observed by Wood 
and Loomis with 200–500 kHz high intensity ultrasound 
(Wood and Loomis 1927).
In contrast to ultrasound used for diagnostic imaging, 
therapeutic ultrasound can be described as a controlled 
sound wave intended for biological interaction for a curative 
beneﬁ  t. Some of the ﬁ  rst clinically signiﬁ  cant application 
of this technology was developed by Francis and William 
Fry in the 1950s (Fry et al 1954; Fry 1954). Their work 
was applied to the development of ultrasound devices for 
noninvasive surgical treatment of neurological disorders 
including Parkinson disease. Results included both revers-
ible and irreversible biological effects. Other early clinical 
applications at this same time include the treatment of 
arthritis using ultrasound with hydrocortisone to relieve 
pain (Fellinger and Schmid 1954).
Thus it is appropriate to divide therapeutic ultrasound 
into two categories which use ‘low’ intensities and ‘high’ 
intensities (5 W/cm2) though this division is not precise 
(ter Haar 1999). High intensity focused ultrasound (HIFU) 
is an attractive means of noninvasive coagulation of deep 
tissues using external sources. Current clinical applications 
of ultrasound include transducer and array designs for the 
treatment of prostate cancer (Gelet et al 2004; Saleh and 
Smith 2004), liver tumors (Li et al 2004; Gignoux et al 
2003), breast cancer (Jenne et al 2003; Wu et al 2004), blad-
der tumors (Wang et al 2003; Madersbacher and Marberger 
2003) and uterine ﬁ  broids (Chan et al 2002; Tempany et al 
2003). Low intensity ultrasound has been shown to mediate 
the transport of drugs across the skin and is clinically used in 
physical therapy to accelerate or stimulate a normal biological 
response through deep heating.
Many recent reviews have shown that ultrasound medi-
ated transdermal drug delivery offers promising potential for 
noninvasive drug administration (Tachibana and Tachibana 
2001; Pitt et al 2004; Mitragotri 2005). The working principle 
of sonophoresis, although not completely understood, has 
been suggested to be the result of cavitation (Mitragotri et al 
1995b, 1997) although thermal effects can not be entirely 
discounted. Low frequency ultrasound is capable of generating 
microbubbles in the water and tissue. Because sound energy 
is transmitted in a ﬂ  uid media, the large negative pressures 
cause violent collapse in bubbles, which results in the forma-
tion of water channels within the lipid bilayers. The resulting 
disorder created in the stratum corneum facilitates the crossing 
of a hydrophilic drug or molecule.
Table 1 sets out an overview of the transdermal ultrasound 
mediated drug delivery literature from the past several years 
with some commentary on notable contributions. Though not 
complete, the table lists the delivered compound or drug, its 
respective molecular weight (Daltons) and the experimental 
sample (animal) preparation including whether the experi-
ment was performed under in vivo or in vitro conditions. Of 
major interest is the ability to reduce the research to clinical 
practice and therefore the reported ultrasound frequency 
and device is listed. For the table, ultrasound devices can be 
classiﬁ  ed into different categories. The commercially made 
devices include sonicators (≈20 kHz), ultrasound heating 
devices intended for therapy (1 MHz) and pre-fabricated 
transducers. Very few of the ultrasound devices listed are 
speciﬁ  cally designed for drug delivery and originally, like 
the sonicator, had a different intended purpose.
Many previous investigators using sonophoresis have found 
enhanced transdermal drug delivery over various frequency 
ranges using commercial sonicators or therapeutic devices. 
For example, a 14-fold increase of corticosterone transport 
has been shown using a 1 MHz therapeutic product used 
for the treatment of chronic and acute pain (Sonopuls® 463, 
Sugarland, TX) operating at 1.4 W/cm2 for 24 hours (Johnson 
et al 1996). Signiﬁ  cant transdermal transport of model drugs 
such as mannitol and inulin (plant starch) has been observed 
using a 20 kHz commercial sonicator (VCX400, Sonics and 
Materials, Newtown, CT) (Levy et al 1989). Previous work 
with high frequency ultrasound (≈1 MHz and at 1–3 W/cm2) 
to enhance transdermal drug delivery has produced interesting 
results, which varied from drug to drug (Bommannan et al 
1992a, 1992b; Mitragotri et al 1997). Pulsed ultrasound at 
1 MHz has been used to increase transdermal absorption of 
indomethacin from an ointment in rats (Asano et al 1997). A 
combination of chemical enhancers and therapeutic ultrasound International Journal of Nanomedicine 2007:2(4) 587
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Table 1 A list of transdermally delivered drugs and compounds using ultrasound devices
Compound M.W  Preparation  Frequency  Device  Investigator
Aldosterone   832  in vitro human  20 kHz  Sonicator1  (Johnson et al 1996)
Benzene   78  in vitro human  1–3 MHz  Therapeutic5  (Mitragotri et al 1995b)
Bicarbonate   136  in vivo rat  20 kHz  Sonicator1  (Mitragotri et al 2000b)
Butanol   74  in vitro human  1–3 MHz  Therapeutic5  (Mitragotri et al 1995b)
Butanol   74  in vitro human  20 kHz  Sonicator1  (Johnson et al 1996)
Caffeine   194  in vitro human  1–3 MHz  Therapeutic5  (Mitragotri et al 1995b)
Caffeine   194   in vitro human  20 kHz  +++  (Boucaud et al 2001)
Caffeine   194   in vitro rat  20 kHz  +++  (Boucaud et al 2001)
Calcein  623  in vitro rat  41, 158, 445 kHz  US transducer13  (Mutoh et al 2003)
Calcein  623  in vitro cell membrane  20, 57, 76, 93 kHz  US transducer17  (Sundaram et al 2003)
Calcein  623  in vitro porcine   20 kHz  US transducer21  (varez-Roman et al 2003)
Calcein  623  in vitro pig  20 kHz  Sonicator1  (Kushner et al 2004)
Calcein  623  in vitro rat  41 kHz  US transducer9  (Morimoto et al 2005)
Calcium   40  in vivo rat  20 kHz  Sonicator1  (Mitragotri et al 2000b)
Corticosterone   346  in vitro human  1 MHz  Therapeutic US2  (Johnson et al 1996)
Corticosterone   346  in vitro human  1–3 MHz  Therapeutic US5  (Mitragotri et al 1995b)
Corticosterone   346  in vitro human  20 kHz  Sonicator1  (Johnson et al 1996)
Dexamethasone   392  in vitro human  1 MHz  Therapeutic US2  (Johnson et al 1996)
Dexamethason  392  in vivo human  1 MHz  US transducer10  (Darrow et al 1999)
Dextran++   2000  in vivo rat  20 kHz  Sonicator1  (Mitragotri et al 2000b)
Dextran  70000  in vitro pig  58 kHz  US transducer17  (Tezel et al 2003)
Diclofenac  296  in vivo human  1 MHz  Therapeutic  (Rosim et al 2005)
Diclofenac 296    in vivo rat  1 MHz  Sonicator12  (Hsieh 2006)
Erythropoeitin   48000  in vitro human,  20 kHz  Sonicator1  (Mitragotri et al 1995a)
Estradiol   272  in vitro human  1 MHz  Therapeutic US2  (Johnson et al 1996)
Estradiol   272  in vitro human  1–3 MHz  Therapeutic US5  (Mitragotri et al 1995b)
Estradiol   272  in vitro human  20 kHz  Sonicator1  (Mitragotri et al 1996)
FD-4*  4400  in vitro rat  41 kHz  US transducer9  (Morimoto et al 2005)
FD-40*  38000  in vitro rat  41 kHz  US transducer9  (Morimoto et al 2005)
Fentanyl  336  in vitro human  20 kHz  +++  (Boucaud et al 2001)
Fentanyl 336    in vitro rat  20 kHz  +++  (Boucaud et al 2001)
FITC****  51000  in vitro human  20 kHz  Soniﬁ  er19  (Weimann and Wu 2002)
FITC****   2500  in vitro human  20 kHz  Soniﬁ  er19  (Weimann and Wu 2002)
Fluorescein  389  in vitro human  20 kHz  Sonicator14  (Cancel et al 2004)
Fluorescein probes nile red  535  in vitro porcine  20 kHz  US transducer21  (varez-Roman et al 2003)
Glucose   182  in vivo rat  20 kHz  Sonicator1  (Mitragotri et al 2000b)
Glucose   182  in vitro human  20 kHz  Sonicator1  (Kost et al 1996)
Glucose   182  in vitro porcine  10 MHz  US transducer20  (Merino et al 2003)
Glucose   182  in vitro porcine  20 kHz  Sonicator21  (Merino et al 2003)
Glucose   182  in vivo rat  20 kHz  cymbal TDR  (Lee et al 2005)
Hyaluronan  1000  in vivo rabbit  1 MHz  Therapeutic  (Park et al 2005)
Hydrocortisone  362  in vivo rat  1 MHz  Therapeutic  (Koeke et al 2005)
Ibuprofen  206  in vivo human  1 MHz  UStransducer23  (Kozanoglu et al 2003)
Insulin  5807  in vitro human, in vivo rat  20 kHz  Sonicator1  (Mitragotri et al 1995a)
Insulin  5807  in vivo rat  20 kHz  Sonicator1  (Boucaud et al 2000)
Insulin  5807  in vivo rat  48 kHz  LAG-264  (Tachibana and Tachibana 1991)
Insulin  5807  in vivo rabbit  105 kHz  LAG-264   (Tachibana 1992)
Insulin  5807  in vivo rabbit  105 kHz  UStransducer9   (Tachibana 1992)
Insulin  5807  in vitro human  20 kHz  Sonicator6  (Zhang et al 1996)
Insulin  5807  in vivo rat  20 kHz  Sonicator1  (Boucaud et al 2002)
Insulin  5807  in vitro human  20 kHz  cymbal TDR  (Smith et al 2003)
Insulin  5807  in vivo rat  20 kHz  cymbal TDR  (Lee et al 2004a)
Insulin  5807  in vivo rabbit  20 kHz  cymbal TDR  (Lee et al 2004b)
Inulin   5000  in vivo rat  20 kHz  Sonicator1  (Mitragotri and Kost 2000)
Inulin   5000  in vitro pig  58 kHz  US transducer17  (Tezel et al 2003)
Ketoprofen  254  in vivo human  1 MHz  Sonicator22  (Cagnie et al 2003)
Ketorolac-tromethamine  376  in vitro rat  1 MHz  Sonicator7  (Tiwari et al 2004)
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Table 1 (Continued)
Compound M.W  Preparation  Frequency  Device  Investigator
Lanthanum droxide  189  in vivo guinea pigs  2, 10, 16 MHz  Panametrics3  (Bommannan et al 1992a)
Lidocaine   234  in vitro human  1 MHz  Therapeutic2  (Johnson et al 1996)
Linoleic acid   280  in vitro human  1 MHz  Therapeutic2  (Johnson et al 1996)
Luteinizing hormone  1311  in vitro pig  58 kHz  US transducer17  (Tezel et al 2003)
Mannitol   183  in vivo rat  20 kHz  Sonicator1  (Mitragotri and Kost 2000)
Mannitol   183  in vitro pig  20 kHz  Sonicator1   (Mitragotri et al 2000c)
Mannitol   183  in vivo rat  20 kHz  Sonicator1   (Mitragotri and Kost 2000)
Mannitol   183  in vitro pig, in vitro human  20 kHz  US transducer1  (Tang et al 2001)
Mannitol   183  in vitro pig, in vivo pig  20 kHz  US transducer1   (Tang et al 2002)
Mannitol   183  in vitro pig  20 kHz  Sonicator1   (Terahara et al 2002)
Mannitol   182  in vitro pig  58 kHz  US transducer17   (Tezel et al 2003)
Mannitol   183  in vitro porcine  10 MHz  US transducer20   (Merino et al 2003)
Mannitol   183  in vitro porcine  20 kHz  Sonicator21   (Merino et al 2003)
Methylpredni-solone/  374  in vivo human  25 kHz  Sonicator7  (Santoianni et al 2004)
 cyclosporine
Oligonucleotides  +++  in vitro pig   20 kHz   Sonicator1  (Tezel et al 2004)
Progesterone   274  in vitro human  1–3 MHz  Therapeutic5  (Mitragotri et al 1995b)
Salicylic acid   138  in vitro human  20 kHz  Sonicator1  (Johnson et al 1996)
sodium lauryl sulfate  288  in vitro pig  19.6, 36.9, 58.9,   US transducer17  (Tezel et al 2001)
      76.6, 93.4 kHz
sodium lauryl sulfate  288   in vitro pig  20 kHz  US transducer11  (Tezel and Mitragotri 2003)
sodium lauryl sulfate  288   in vitro porcine  20 kHz  Sonicator11  (Paliwal et al 2006)
Sucrose  342  in vitro human  20 kHz  Sonicator1  (Johnson et al 1996)
Sucrose  342  in vitro human, pig  20 kHz  US transducer1   (Tang et al 2001)
Testosterone  288  in vitro human  1 MHz  Therapeutic2  (Johnson et al 1996)
Tetanus Toxoid (TTx vaccine)  150000  in vivo mice  20 kHz  600W Sonicator11  (Tezel et al 2005)
Triamcinolone- Acetonide  434  in vitro mice  1, 3 MHz  US transducer9  (Yang et al 2006)
Urea  60  in vivo rat  20 kHz  Sonicator1  (Mitragotri et al 2000a)
Vasopressin  1056  in vitro human  20 kHz  Sonicator6  (Zhang et al 1996)
Water  18  in vitro human  20 kHz  Sonicator1  (Johnson et al 1996)
Legend
1. VCX 400, Sonics and Materials Inc., Newtown, CT
2. Sonopuls 463, Henley International
3. Precision Acoustic Devices and Panametrics
4. Leader Electronics Corp., Japan
5. Sonopuls 474, Henley International
6. W-385, Heat Systems Ultrasonics, Inc.
7. Brand not indicated
8. Cole Palmer Instrument Co, Chicago, IL
9. Transducer company not indicated
10. Omnisound 3000, Accelerated Care Plus-Physio Technology Inc., Topeka, KS.
11. Sonics and Materials, Newtown, CT
12. ITO Co, 1-23-15, Hakusan, Bunkyo-ku, Tokyu, Japan
13. Dai-ichi High Frequency, Tokyo, Japan
14. Model XL2020, Misonix Inc., Farmingdale, NY
15. Pro Seven 977 to 2000 model, Quark Productos Médicos, Brazil
16. NoblelifeTM , Duplogen, Suwon, Korea
17. Piezo Systems, Cambridge, MA
18. Transducers made in-house
19. Model S-110, Branson Instruments Inc., Standford, CT
20. Sofranel, Zurich, Switzerland
21. VCX 400, Sonics and Materials Inc., Danbury, CT
22. Sonoplus 590, Enraf-Nonius BV, AV Delft, the Netherlands
23. Peterson®250 Ultrasound Equipment Petaş, Turkey
+++details not indicated.
*FITC-labeled dextrans.
***PBS solution was prepared using Milli-Q® water and a phosphate concentration of 0.01 M and NaCl concentration of 0.137 M.
****Fluorescein Isothiocyanate (FITC).
Note:  Apologies are offered for any missing information.
Abbreviations: US, ultrasound; Therapeutic, commercially made ultrasound device for heating therapy; TDR, transducer.International Journal of Nanomedicine 2007:2(4) 589
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(1 MHz, 1.4 W/cm2, continuous wave (CW)) in transdermal 
drug transport has also been investigated with success (John-
son et al 1996).
A noteworthy difference between high (1–3 MHz) and 
low (≈20 kHz) frequency ultrasound appears to be that low 
frequency ultrasound enhances transdermal drug transport 
1000 times more than high frequency ultrasound (Mitragotri 
et al 1996). The working hypothesis for the physical mecha-
nism is that low-frequency ultrasound enhances transdermal 
transport through aqueous channels in the stratum corneum 
generated by cavitation induced bilayer disordering. However, 
the mechanism of the enhancement using ultrasound is far 
from being fully understood (Pitt et al 2004). Some research-
ers have concluded that at 168 kHz using CW ultrasound and 
at 1.9* × 105 Pa, a new structural state was induced which 
generated defects in human stratum corneum specimens. They 
suggest that the dimensions of the defects (20 μm) were large 
enough to allow the transdermal passage of high molecular 
weight drug molecules, which normally elude the unenhanced 
transdermal drug delivery (Wu et al 1998).
Past research has demonstrated the possibility of deliv-
ering and controlling therapeutic doses of proteins such as 
interferon gamma and erythropoeitin across human skin 
using ultrasound (Mitragotri et al 1995a). Other researchers 
have investigated the in vitro penetration and the in vivo 
transport of ﬂ  ufenamic acid in skin with ultrasound (Hippius 
et al 1998). In the ﬂ  ufenamic acid study, ultrasound exposure 
was from 5–30 minutes with intensities up to 1.5 W/cm2. 
Although there was a pronounced effect of ultrasound on the 
transmembrane absorption of the drug, there was also a rise in 
temperature up to 4.5 °C. Ultrasound at 1 MHz has also been 
used to enhance the transdermal absorption of indomethacin 
studied in rats using intensities from 0.25–1 W/cm2. The 
researchers reported no signiﬁ  cant skin temperature rise and 
no notable damage to the skin, although damage was noted 
as the intensity and the time of application of ultrasound 
increased beyond 1 W/cm2 (Miyazaki et al 1992).
Other researchers have reported noticeable skin damage 
from ultrasound transdermal drug delivery experiments (Wu 
et al 1998). One group has examined the morphological 
changes induced in in vitro hairless mouse skin and human 
skin after ultrasound exposure to transdermal drug delivery 
systems. The skins were immersed in a commercial ultra-
sound water tank at 48 kHz and an intensity of 0.5 W/cm2. 
Skins were compared to control skins under a scanning 
electron microscope. The researchers found that cells of 
the stratum corneum of the mouse skin surface were almost 
completely removed. Furthermore, on some of the the mouse 
samples, large craterlike pores with a diameter of 100 microns 
were formed sporadically. However in human skin, the 
surface exposed to ultrasound showed only slight removal 
of keratinocytes around the hair follicles. The researchers 
suggested that the removal of the stratum corneum and other 
alterations in hairless mouse and human skin may explain 
the enhancement of transdermal drug penetration (Yamashita 
et al 1997).
Convenient noninvasive methods for transdermal deliv-
ery of insulin or similar procedures for glucose sensing has 
particular public interest due to the increasing problem of 
diabetes. In the United State alone, approximately 16 mil-
lion people suffer from diabetes mellitus. From a human and 
economic perspective, it is one of the most costly diseases 
(Congressionally Established Diabetes Research Working 
Group 1999; The Whitaker Foundation 2004). Management 
of diabetes often requires painful repetitive blood glucose 
tests and insulin injections up to three or four times each 
day. Between injections, blood sugar levels can ﬂ  uctuate 
and remain out of balance until the next test or injection, 
increasing the risk of tissue or organ damage.
Speciﬁ  cally for insulin (Table 1), the amount of research 
for noninvasive insulin delivery is increasing every year. 
Over a frequency range of 20–105 kHz, enhanced transport 
in the presence of ultrasound has been shown in both in vitro 
and in vivo experiments. Many early experiments were per-
formed using either an ultrasound sonicator, ultrasonic bath 
or commercial transducer. For example investigators have 
demonstrated effective in vivo transport of insulin at 48 kHz 
using an ultrasonic bath (Tachibana and Tachibana 1991) and 
at 105 kHz (Tachibana 1992) using a commercially obtained 
transducer. The major drawback so far in exploiting ultra-
sound for noninvasive drug delivery is the large size and poor 
mobility of the ultrasound device. Commercial sonicators are 
large, heavy, table-top devices speciﬁ  cally designed for lysis 
of cells, catalyzing reactions, creating emulsions or cleaning. 
A few commercial ultrasound devices do exist, speciﬁ  cally 
designed for ultrasound drug delivery, such as the SonoPrep® 
made by the Sontra Medical Corporation (Cambridge MA), 
which is a large ultrasound device that consists of a power 
control unit and a hand-held applicator.
Although diabetics have an aversion to injecting insulin 
they probably hate the more frequent ﬁ  nger-stick for blood 
glucose samples even more. A number of different tech-
niques for monitoring blood glucose using non-invasive 
or minimally invasive methods are under investigation 
including near-infrared spectroscopy, implantable glucose 
sensors, reverse sonophoresis, reverse iontophoresis and International Journal of Nanomedicine 2007:2(4) 590
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interstitial ﬂ  uid sampling devices (Kost 2002). The latter 
three techniques extract glucose transdermally and measure 
glucose in interstitial ﬂ  uid. Dermal interstitial ﬂ  uid glucose 
concentration is highly correlated with the plasma glucose 
concentration and capillary blood glucose concentration. 
Thus transdermal extraction of interstitial ﬂ  uid offers a 
noninvasive method of obtaining a sample for blood glucose 
measurements (Cantrell et al 2000; Kost 2002). Previous 
results has demonstrated positive results in the use of ultra-
sound to facilitate the noninvasive extraction of interstitial 
skin ﬂ  uids (ISF) for blood glucose monitoring through an 
electrolytic reaction with glucose sensitive enzymes (Kost 
et al 2000).
Mechanism of ultrasound
Although ultrasound is known to increase transdermal pro-
tein delivery (Tachibana 1992; Mitragotri et al 1995a) the 
mechanisms of this enhanced transport have not been fully 
characterized (Pitt et al 2004). Bioeffects from ultrasound 
include the thermal or mechanical (cavitation) mechanism 
(AIUM 2000). One effect of cavitating ultrasound is its 
ability to increase permeability of the outer skin layer (stra-
tum corneum), which is thought to be a primary barrier to 
protein diffusion. Cavitation represents the rapid expansion 
and collapse of gaseous bubbles in response to an alternat-
ing pressure ﬁ  eld. Cavitation types can be broken into two 
non-exclusive categories (Flynn 1982). The ﬁ  rst is stable 
cavitation where the cavity oscillates about its equilibrium 
radius in response to relatively low acoustic pressures. 
The second is transient cavitation (also known as inertial 
cavitation) whereby the equilibrium size varies greatly in 
response to very few acoustic cycles. During transient cavi-
tation, the rapid, violent collapse of bubbles is associated 
with high acoustic pressures and temperatures of the order 
of 1000–2000 K (Apfel 1981, 1986). Transient cavities are 
generated in response to high acoustic pressures and/or lower 
frequencies. The violent hydrodynamic forces (Figure 1) 
due to a collapsing bubble can cause severe damage within 
biological media. Indeed free radicals can be produced by 
this violent phenomena (Edmonds and Sancier 1983; Mason 
and Lorimer 1988).
There exists several definitions for the threshold for 
transient cavitation in terms of such physical parameters as 
acoustic pressure, frequency or bubble radius. For diagnostic 
ultrasound, one (of many) deﬁ  nitions of the cavitation onset 
is the peak rarefractional pressure divided by the square root 
of the frequency (Apfel and Holland 1991). From previous 
research, the measured cavitation pressure amplitude in dog 
thigh muscle in vivo was found to depend linearly on frequency 
with a slope of 5.3 MPa/MHz (Hynynen 1990). Compared to 
the kilohertz range, ultrasound in the megahertz range also pro-
duces cavitation although much higher pressures are required 
to exceed the cavitation threshold. Beyond the threshold, 
cavitation has been shown to disrupt cells and damage tissue 
(Dalecki et al 1996; Miller et al 1996). Mechanical bioeffects 
in tissues with gas bodies include lung hemorrhage in mice, 
rats, monkeys and pigs (AIUM 2000). Cavitation has also been 
shown with diagnostic ultrasound levels (Apfel 1986; Roy et al 
1990) which has motivated the introduction of the mechanical 
index to identify a threshold pressure for the onset of inertial 
cavitation (AIUM-NEMA 1996). Even in the absence of 
well-deﬁ  ned gas bodies, there exist non-thermal bioeffects 
due to ultrasound, which are known to occur in the absence 
of excessive heating or evidence of cavitation bubbles. In this 
situation, the mechanism is in the form of radiation force or 
torque or acoustic streaming (Beyer 1997).
The dynamics of acoustic cavitation in liquid alone 
differ considerably to cavitation at liquid-solid interfaces. 
Ultimately acoustic bubble dynamics are quite complex 
and beyond this overview (Apfel 1981; Leighton 1994; 
Hamilton and Blackstock 1998). Determining the threshold 
and energy from a cavitation event is difﬁ  cult under the best 
conditions. Researchers in ultrasound try to follow three 
experimental rules with respect to cavitation: understand 
the liquid including impurities, understand the sound ﬁ  eld, 
and know when something happens (Apfel 1981). The ﬁ  rst 
rule refers to the cavitation threshold while the second rule 
relates to accurate measurements of the acoustic ﬁ  eld. The 
third relates to observable cavitation events or secondary 
related information. Rule two deals with a commentary 
regarding information which could have been included in 
Table 1 but was intentionally omitted. Though many of the 
papers listed in Table 1 report an ultrasound intensity, the 
drawback is that much of the literature gives a value but 
does not specify details of the exposimetry such as spatial 
(average, peak) or temporal (average, peak) values. To 
report the determination of an acoustic ﬁ  eld, it is essential 
to supply enough information, such as calibrated hydro-
phones, dissolved gas concentration, anechoic conditions, 
etc., so that intensity experiments can be repeated by oth-
ers. Therefore accurate and precise evaluation of acoustic 
ﬁ  elds should follow exposimetry and dosimetry procedures 
previously recognized in the ultrasound literature (Schafer 
et al 1990; Lewin and Ziskin 1992; AIUM-NEMA 1996; 
Lewin et al 2003). Without such information, comparing 
the intensity of enhanced transport between many of the International Journal of Nanomedicine 2007:2(4) 591
Transdermal ultrasound mediated drug delivery
drug delivery publications, or determining potential bioef-
fects, is impossible.
Future of transdermal drug delivery
Use of transdermal drug delivery techniques has the most 
practical clinical application for medications which need to 
be injected multiple times either daily or weekly. Though 
infrequent, other injectable drug avoidance situations could 
include the use of needles on infants, children and pets or under 
harsh conditions (battleﬁ  eld or ﬁ  rst responder) where needles 
are not feasible. As seen in Table 1, many previous researchers 
who have successfully used acoustic energy for drug delivery 
have used commercial sonicators or off-the-shelf transducers. 
These large industrial devices are impractical for a feasible 
and transportable drug delivery device. Much of the previous 
ultrasound transdermal dry delivery research has focused on 
low frequencies primarily because commercial sonicators 
were designed to operate only at one frequency. To bring this 
research to clinical practice will require more investigation 
into the optimal frequency and intensity of each particular 
drug. As with diagnostic ultrasound imaging, drug delivery 
using ultrasound requires a delicate balance between safety 
and efﬁ  cacy and requires careful scientiﬁ  c study.
Other recent reviews on drug delivery state similar 
views to those expressed here, for example, “small-sized 
low-frequency transducers need to be developed so that 
patients can wear them” (Pitt et al 2004). Although there 
are several possible low frequency transducer designs that 
can be used in a drug delivery application, such as the low 
frequency ﬂ  extensional resonators (Stansﬁ  eld 1990), tonpilz 
transducers (Wilson 1988), or “thickness”-type resonators 
(Shung et al 1992), the “cymbal” transducer design is a 
good choice for a portable device. This Class V ﬂ  extensional 
transducer has a thickness of less than 2 mm, weighs less 
than 3 g, resonates between 1 and 100 kHz depending on 
geometry, and has a large scale manufacturing cost of less 
than $5.00/unit (Newnham et al 1991, 1994; Dogan et al 
1997; Newnham, 1998; Tressler et al 1998). With the low 
proﬁ  le cymbal design, high frequency radial motions of the 
ceramic translates into low frequency displacement motions 
through the cap covered cavity. If the diameter of the ceramic 
is increased (ie, a larger single element), then the frequency 
of the transducer decreases towards a lower range. If the 
diameter increased, the capsule depth of the ﬂ  extensional 
design also needs to increase thereby increasing the thickness 
and slightly increasing the proﬁ  le. Cymbals can be arranged 
into multi-element array designs (Figure 2) since this can 
increase the effective aperture of ultrasound area with respect 
to skin area. Some research indicates that the delivery dose 
increases with ultrasound exposure area (Smith et al 2003). 
Figure 1 With transient cavitation the bubble dynamics have two basics stages comprising the initial formations of the cavity followed by the growth and asymmetric 
violent collapse. The photo shows the jet produced by the collapse of a cavitation bubble at a liquid-solid interface. [Photo courtesy of Dr. Lawrence Crum at the University 
of Washington.]International Journal of Nanomedicine 2007:2(4) 592
Smith
Interestingly the cymbal design originates from underwa-
ter research for naval applications and current research is 
underway to incorporate existing battery technology in the 
miniaturization of portable power for both insulin delivery 
and glucose sensing (Lee et al 2004, 2005).
In general the future for noninvasive drug delivery is 
encouraging. Exploiting transdermal ultrasound drug deliv-
ery beyond the feasibility stage will require the cooperation 
of medical doctors and engineers so that the technology 
aids the construction of a clinical device. As with diagnostic 
ultrasound, the bioeffects and safety of each device needs to 
be carefully monitored, because it will not matter how much 
of any drug can be transported if the skin is burned, damaged 
or the procedure is painful.
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